Journal
JOURNAL OF CLINICAL LIPIDOLOGY
Volume 8, Issue 5, Pages 473-488Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2014.07.007
Keywords
Clinical recommendations; Dyslipidemia; Atherogenic cholesterol; Low-density lipoprotein cholesterol; Lipoproteins; Atherosclerotic cardiovascular disease; Coronary heart disease
Categories
Funding
- Merck and Co.
- Amarin
- AstraZeneca
- Regeneron/Sanofi-Aventis
- Kowa Pharmaceuticals
- Abbott Laboratories
- Matinas BioPharma
- Astra Zeneca
- Pharmavite
- Trygg Pharmaceuticals
- Merck
- Arena Pharmaceuticals
- Boehringer Ingelheim
- Cargill Inc.
- GlaxoSmithKline
- Novo Nordisk
- Orexigen Therapeutics
- Shionogi
- Takeda
- Stratum Nutrition
- California Raisin Board
- Esperion
- Essentialis
- Forest
- Gilead
- Given
- Hoffman LaRoche
- Home Access
- Novartis
- Omthera
- Pfizer
- TWI Bio
- Xoma
- Ardea Inc.
- High Point Pharmaceuticals
- LLC
- Micropharma Limited
- Transtech Pharma, Inc.
- TIMI
- Pozen
- Regeneron
- Elcelyx
- Amgen
- Bristol-Myers Squibb
- Catabasis
- Daiichi Sankyo, Inc.
- Eisai
- VIVUS
- Zeomedex
- WPU
- Sanofi
- Lily
- Philips Medical Systems
- Merck Sharpe Dohme
- Novo Nordisk Inc.
- Genzyme
- Pfizer, Inc.
- LipoScience, Inc.
- Medtelligence
- Vindico
Ask authors/readers for more resources
Various organizations and agencies have issued recommendations for the management of dyslipidemia. Although many commonalities exist among them, material differences are present as well. The leadership of the National Lipid Association (NLA) convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. The current Executive Summary highlights the major conclusions in Part 1 of the recommendations report of the NLA Expert Panel and includes: (1) background and conceptual framework for formulation of the NLA Expert Panel recommendations; (2) screening and classification of lipoprotein lipid levels in adults; (3) targets for intervention in dyslipidemia management; (4) atherosclerotic cardiovascular disease risk assessment and treatment goals based on risk category; (5) atherogenic cholesterol-non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol as the primary targets of therapy; and (6) lifestyle and drug therapies intended to reduce morbidity and mortality associated with dyslipidemia. (C) 2014 National Lipid Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available